We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+5%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$40.3B
AUM Growth
+$535M
(+1.3%)
Cap. Flow
-$468M
Cap. Flow
% of AUM
-1.16%
Top 10 Holdings %
Top 10 Hldgs %
15.78%
Holding
2,279
New
170
Increased
711
Reduced
1,071
Closed
189
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$178M |
| 2 |
LyondellBasell Industries
LYB
|
+$133M |
| 3 |
AT&T
T
|
+$124M |
| 4 |
Stanley Black & Decker
SWK
|
+$101M |
| 5 |
Pfizer
PFE
|
+$93.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Clorox
CLX
|
+$229M |
| 2 |
Gilead Sciences
GILD
|
+$164M |
| 3 |
Broadcom
AVGO
|
+$149M |
| 4 |
KeyCorp
KEY
|
+$145M |
| 5 |
Darden Restaurants
DRI
|
+$125M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.22% |
| 2 | Technology | 14.47% |
| 3 | Financials | 10.84% |
| 4 | Industrials | 9.01% |
| 5 | Consumer Discretionary | 8.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1426
Sabra Healthcare REIT
SBRA
$5.13B
| $397K | ﹤0.01% |
33,753
+1,874
| +6% | +$21.3K |
|
|
AMK
1427
DELISTED
AssetMark Financial Holdings, Inc.
AMK
| $396K | ﹤0.01% |
+13,360
| New | +$392K |
|
|
OKUR
1428
OnKure Therapeutics
OKUR
$117M
| $396K | ﹤0.01% |
6,037
-1,802
| -23% | -$145K |
|
|
TDCX
1429
DELISTED
TDCX Inc. American Depositary Shares, each representing one Class A ordinary share
TDCX
| $396K | ﹤0.01% |
50,000
+10,000
| +25% | +$82.4K |
|
1430
Alexandria Real Estate Equities
ARE
$9.21B
| $394K | ﹤0.01% |
3,472
-562
| -14% | -$66.9K |
|
1431
American Homes 4 Rent
AMH
$11.3B
| $393K | ﹤0.01% |
11,100
+4,500
| +68% | +$153K |
|
1432
Assembly Biosciences
ASMB
$519M
| $393K | ﹤0.01% |
28,488
-1,764
| -6% | -$21.7K |
|
1433
ACI Worldwide
ACIW
$5.21B
| $384K | ﹤0.01% |
16,588
-218
| -1% | -$5.27K |
|
1434
Skyward Specialty Insurance
SKWD
$2.54B
| $384K | ﹤0.01% |
15,117
-208,210
| -93% | -$4.81M |
|
|
GIFI
1435
DELISTED
Gulf Island Fabrication
GIFI
| $383K | ﹤0.01% |
117,949
-52
| -0% | -$176 |
|
|
CTRA
1436
DELISTED
Coterra Energy
CTRA
| $382K | ﹤0.01% |
15,097
-7,776
| -34% | -$193K |
|
1437
UMB Financial
UMBF
$10.2B
| $381K | ﹤0.01% |
6,263
-2,929
| -32% | -$175K |
|
1438
The Kraft Heinz Company
KHC
$29.3B
| $381K | ﹤0.01% |
10,742
-87,429
| -89% | -$3.36M |
|
1439
Arcutis Biotherapeutics
ARQT
$3.29B
| $381K | ﹤0.01% |
40,000
+10,000
| +33% | +$111K |
|
1440
Vale
VALE
$60.1B
| $380K | ﹤0.01% |
+28,310
| New | +$401K |
|
1441
Arrowhead Research
ARWR
$9.29B
| $378K | ﹤0.01% |
10,596
+1,055
| +11% | +$36.4K |
|
1442
CNX Resources
CNX
$4.99B
| $377K | ﹤0.01% |
21,286
-3,506
| -14% | -$56.6K |
|
1443
Ferguson
FERG
$41.5B
| $376K | ﹤0.01% |
+2,388
| New | +$340K |
|
|
EVA
1444
DELISTED
Enviva Inc.
EVA
| $375K | ﹤0.01% |
34,605
+2,840
| +9% | +$41.3K |
|
1445
InMode
INMD
$839M
| $374K | ﹤0.01% |
10,000
| – | – |
|
1446
Charter Communications
CHTR
$16.1B
| $371K | ﹤0.01% |
1,011
+84
| +9% | +$28.7K |
|
1447
Royalty Pharma
RPRX
$26B
| $369K | ﹤0.01% |
12,000
| – | – |
|
1448
Agios Pharmaceuticals
AGIO
$1.97B
| $366K | ﹤0.01% |
12,936
-2,328
| -15% | -$57.9K |
|
1449
Amphenol
APH
$191B
| $361K | ﹤0.01% |
16,992
+3,548
| +26% | +$68.9K |
|
1450
Similarweb
SMWB
$736M
| $361K | ﹤0.01% |
55,000
+15,000
| +38% | +$91K |
|
Similar funds
Federated Hermes's Q2 2023 Portfolio in Review
As of Q2 2023, Federated Hermes held 2,279 positions worth $40.3B, up 1.3% from $39.7B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Federated Hermes's Q2 2023 filing shows 170 new, 711 increased, 1,071 reduced and 189 closed positions. Its largest new stake was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M. The largest sale was Clorox, an estimated $229M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 20% a quarter earlier, followed by Technology and Financials.
- Federated Hermes's largest Q2 2023 buy was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M.
- Federated Hermes added most to Amgen in Q2 2023, an estimated $178M increase.
- Federated Hermes's biggest Q2 2023 reduction was Clorox, cutting an estimated $229M.
- Federated Hermes fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $55.4M.
- Federated Hermes's ten largest holdings make up 16% of its $40.3B portfolio in Q2 2023.
- Federated Hermes opened 170 new positions and closed 189 in Q2 2023.
- Federated Hermes's portfolio value rose 1.3% quarter-over-quarter to $40.3B.
Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.